Summary
2IVB Chart
Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered second SUBLOCADE injection a week later vs. standard 28 days, enabling patients to achieve and maintain target medication levels more quickly.
October 1, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against INDV
NEW YORK, NY / ACCESSWIRE / September 28, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
October 1, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against INDV
NEW YORK, NY / ACCESSWIRE / September 25, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Indivior PLC Dividends
| INDV INDV 16 Jun 2016 Paid | Other | $0.47 Per Share |
| INDV INDV 17 Sep 2015 Paid | Other | $0.16 Per Share |
Indivior PLC Earnings
| 9 May 2025 Date | | 0.29 Cons. EPS | 0.41 EPS |
| 20 Feb 2025 Date | | 0.26 Cons. EPS | 0.32 EPS |
| 24 Oct 2024 Date | | 0.31 Cons. EPS | 0.03 EPS |
| 10 Oct 2024 Date | | - Cons. EPS | - EPS |
| 25 Jul 2024 Date | | 0.4 Cons. EPS | - EPS |
| INDV INDV 16 Jun 2016 Paid | Other | $0.47 Per Share |
| INDV INDV 17 Sep 2015 Paid | Other | $0.16 Per Share |
| 9 May 2025 Date | | 0.29 Cons. EPS | 0.41 EPS |
| 20 Feb 2025 Date | | 0.26 Cons. EPS | 0.32 EPS |
| 24 Oct 2024 Date | | 0.31 Cons. EPS | 0.03 EPS |
| 10 Oct 2024 Date | | - Cons. EPS | - EPS |
| 25 Jul 2024 Date | | 0.4 Cons. EPS | - EPS |
Indivior PLC (2IVB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Indivior PLC ever had a stock split?
Indivior PLC Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Joseph J. Ciaffoni CEO | XSTU Exchange | GB00BN4HT335 ISIN |
| US Country | 1,030 Employees | - Last Dividend | - Last Split | 29 Dec 2014 IPO Date |
Overview
Indivior PLC operates within the pharmaceutical industry, focusing on the development, manufacture, and sale of buprenorphine-based prescription drugs aimed at treating opioid dependence and related disorders. With a global presence, including significant operations in the United States, the United Kingdom, and other international markets, the company spearheads initiatives to address substance use disorders, serious mental illnesses, and opioid overdose. Established in 2014, Indivior's mission is underscored by its commitment to offer innovative therapeutic solutions, catering to a range of needs within the ambit of opioid use disorder (OUD) and beyond. Headquartered in North Chesterfield, Virginia, Indivior leverages its scientific and operational expertise to advance a pipeline of products and services designed to improve patient outcomes in the areas of substance abuse and mental health.
Products and Services
- SUBLOCADE and SUBUTEX PRO: Buprenorphine extended-release monthly injections, these are core marketed products designed for the sustained management of opioid use disorder. SUBLOCADE is administered as an injectable while SUBUTEX PRO offers a similar long-term relief in managing addiction symptoms.
- SUBOXONE: Available both as a sublingual film and a tablet, SUBOXONE combines buprenorphine and naloxone. This formulation is aimed at reducing opioid cravings and withdrawal symptoms while blocking the high effects of opioid use, thus facilitating recovery and maintenance therapy for those battling opioid addiction.
- SUBUTEX: This is a buprenorphine sublingual tablet formulated to suppress symptoms of opioid withdrawal. By providing a buprenorphine-only product, SUBUTEX is another avenue for patients seeking opioid dependency treatment with a focus on reducing the potential for misuse.
- OPVEE Nasal Spray: A naloxone-based nasal spray, OPVEE is crafted for the rapid reversal of opioid overdose. Its intranasal delivery system is designed for easy administration, making it an essential tool in emergency situations involving opioid intoxication.
- PERSERIS: A long-acting injectable suspension for the treatment of schizophrenia in adults, PERSERIS employs extended-release technology to provide patients with a consistent delivery of medication, aimed at improving the management of schizophrenia symptoms over time.
- Research and Development: Indivior is actively engaged in developing a diverse pipeline of treatments for substance use disorders and mental illnesses. Notably, INDV-2000, a promising orexin-1 receptor antagonist, is under clinical trials for opioid use disorder. Collaboration with ADDEX Therapeutics has resulted in INDV-1000, targeting alcohol use disorder, while partnership with Alar Pharmaceuticals Inc. focuses on INDV-6001, a long-acting injectable for OUD. The company's venture into digital therapeutics is highlighted by its development of CT-102 with Click Therapeutics for OUD treatment. Additionally, INDV-5004, aimed at treating acute cannabinoid overdose, and AEF0117, developed in partnership with Aelis Farma for cannabis use disorder, further exemplify Indivior's commitment to addressing a broad spectrum of substance-related disorders.
Contact Information
